Go to content Go to menu Go to search

Sanofi-Aventis builds a new vaccine manufacturing facility in Neuville-sur-Saône, France

14 May 2009

  • version française

Sanofi-Aventis new vaccine manufacturing facility

Sanofi-aventis, the world's leading vaccine manufacturer, officially launched may 12th 2009 the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France, in a ceremony attended by

  • Gérard Collomb, Senator and Mayor of Lyon,
  • Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis,
  • Dr. Elias A. Zerhouni, Science and Technology Adviser for sanofi-aventis.

 

The investment in this new vaccine production facility in Neuville-sur-Saône, which is located close to Lyon, in the Southeast of France, amounts to 350 million euros and is the largest investment in Sanofi Pasteur global vaccines industrial network.

This facility will be equipped with state-of-the-art manufacturing technologies and will benefit from the outstanding biological expertise of the Rhône-Alpes region.

It will produce 100 million doses of the novel vaccine against dengue fever, currently under development, employ 200 people, and is expected to be operational in 2013.

Sanofi Pasteur in Lyon

Campus Mérieux in Marcy L'Etoile near Lyon, Sanofi Pasteur's historical site, is now the world's largest campus dedicated to research, development and production of vaccines. The industrial campus hosts 90 buildings over 36 hectares and produces half of Sanofi Pasteur's global vaccine production.